The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated whether inflammatory markers such as neutrophil-lymphocyte ratio (NLR) and platelet- lymphocyte ratio (PLR) independently and in combination would be significant prognostic factors for survival in patients with locally advanced pancreatic cancer. Methods: A total of 497 patients with locally advanced pancreatic cancer who received neoadjuvant or definitive chemoradiotherapy from 2005 to 2015 were evaluated. We divided the patients into groups according to the median values of NLR and PLR: NLR<1.89 (n=156), NLR≥1.89 (n=341), PLR <149 (n=248) and PLR ≥149 (n=249). Results: For NLR <1.89 and ≥1.89 groups, respectively, the 1-year overall survival (OS) rates were 73.2% and 60.8% (p<0.001) and 1-year progressionfree survival (PFS) rates were 43.9% and 31.3% (p<0.001). For PLR <149 and ≥149 groups, respectively, the 1-year OS rates were 68.1% and 61.3% (p=0.029) and 1-year PFS rates were 37.9% and 32.5% (p=0.027). Patients with both high NLR and high PLR showed the worst OS and PFS rates compared with those with both lower NLR and lower PLR. Conclusions: Elevated pretreatment NLR and PLR independently and in combination significantly predicted poor OS and PFS.
Abstract
Background/Aims: We investigated whether inflammatory markers such as neutrophil-lymphocyte ratio (NLR) and platelet- lymphocyte ratio (PLR) independently and in combination would be significant prognostic factors for survival in patients with locally advanced pancreatic cancer. Methods: A total of 497 patients with locally advanced pancreatic cancer who received neoadjuvant or definitive chemoradiotherapy from 2005 to 2015 were evaluated. We divided the patients into groups according to the median values of NLR and PLR: NLR<1.89 (n=156), NLR≥1.89 (n=341), PLR <149 (n=248) and PLR ≥149 (n=249). Results: For NLR <1.89 and ≥1.89 groups, respectively, the 1-year overall survival (OS) rates were 73.2% and 60.8% (p<0.001) and 1-year progressionfree survival (PFS) rates were 43.9% and 31.3% (p<0.001). For PLR <149 and ≥149 groups, respectively, the 1-year OS rates were 68.1% and 61.3% (p=0.029) and 1-year PFS rates were 37.9% and 32.5% (p=0.027). Patients with both high NLR and high PLR showed the worst OS and PFS rates compared with those with both lower NLR and lower PLR. Conclusions: Elevated pretreatment NLR and PLR independently and in combination significantly predicted poor OS and PFS.
참고문헌 (29)
- Siegel RL, "Cancer statistics, 2016", CA Cancer J Clin, 66, pp.7~30 (2016)[DOI]
- Bond-Smith G, "Pancreatic adenocarcinoma", BMJ, 344, pp.e2476~ (2012)[DOI]
- Kamisawa T, "Pancreatic cancer", Lancet, 388, pp.73~85 (2016)[DOI]
- Qi Q, "Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer", Pancreatology, 15, pp.145~150 (2015)[DOI]
- Bhatti I, "Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio", Am J Surg, 200, pp.197~203 (2010)[DOI]
- Elinav E, "Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms", Nat Rev Cancer, 13, pp.759~771 (2013)[DOI]
- Martin HL, "Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer", Intern Med J, 44, pp.676~682 (2014)[DOI]
- Mantovani A, "Cancer-related inflammation", Nature, 454, pp.436~444 (2008)[DOI]
- Goh BK, "Are preoperative blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios useful in predicting malignancy in surgically-treated mucin-producing pancreatic cystic neoplasms?", J Surg Oncol, 112, pp.366~371 (2015)[DOI]
- Spolverato G, "Neutrophil-lymphocyte and platelet-lymphocyte ratio in patients after resection for hepato-pancreatico-biliary malignancies", J Surg Oncol, 111, pp.868~874 (2015)[DOI]
- Inoue D, "Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan", Jpn J Clin Oncol, 45, pp.61~66 (2015)[DOI]
- Stotz M, "Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer", Br J Cancer, 109, pp.416~421 (2013)[DOI]
- Smith RA, "Preoperative plateletlymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma", Am J Surg, 197, pp.466~472 (2009)[DOI]
- Eloubeidi MA, "Prognostic factors for survival in pancreatic cancer: a population-based study", Am J Surg, 192, pp.322~329 (2006)[DOI]
- Humphris JL, "The prognostic and predictive value of serum CA19.9 in pancreatic cancer", Ann Oncol, 23, pp.1713~1722 (2012)[DOI]
- Kishi Y, "Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy", Ann Surg Oncol, 16, pp.614~622 (2009)[DOI]
- Gomez D, "Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma", J Surg Oncol, 97, pp.513~518 (2008)[DOI]
- Luo G, "Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy", Ann Surg Oncol, 22, pp.670~676 (2015)[DOI]
- Lee JM, "Prognostic value of inflammationbased markers in patients with pancreatic cancer administered gemcitabine and erlotinib", World J Gastrointest Oncol, 8, pp.555~562 (2016)[DOI]
- Wang DS, "Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer", Med Oncol, 29, pp.3092~3100 (2012)[DOI]
- Kadokura M, "Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer", J Gastrointest Oncol, 7, pp.982~988 (2016)
- D'Emic N, "Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy", J Gastrointest Oncol, 7, pp.269~277 (2016)
- Shaverdian N, "Pretreatment immune parameters predict for overall survival and toxicity in early-stage non-small-cell lung cancer patients treated with stereotactic body radiation therapy", Clin Lung Cancer, 17, pp.39~46 (2016)[DOI]
- Chen Y, "Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study", BMC Cancer, 16, pp.320~ (2016)[DOI]
- Alagappan M, "Albumin and neutrophil-lymphocyte ratio (NLR) predict survival in patients with pancreatic adenocarcinoma treated with SBRT", Am J Clin Oncol, 41, pp.242~247 (2018)
- Bertuzzo VR, "Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers", Transplantation, 91, pp.1279~1285 (2011)[DOI]
- Whiteside TL, "The tumor microenvironment and its role in promoting tumor growth", Oncogene, 27, pp.5904~5912 (2008)[DOI]
- Shamamian P, "Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis", J Cell Physiol, 189, pp.197~206 (2001)[DOI]
- Di Carlo E, "Neutrophils in the antitumoral immune response", Chem Immunol Allergy, 83, pp.182~203 (2003)